Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, produced mean weight reductions approaching 24% of baseline body weight after 48 weeks at the highest doses in phase 2 trials. Clinical studies tested weekly doses from 1 mg to 12 mg with gradual titration to improve…
# Retatrutide Dosing Guide: Schedules, Safety, and Weight Loss Results
Retatrutide stands out among new drugs for weight loss and metabolic health due to its action as a triple agonist on GLP-1, GIP, and glucagon receptors. In phase 2 trials, participants at the highest doses lost over 24% of their body weight in less than a year. Proper dosing through gradual increases helps balance strong effects with side effect management.
Retatrutide also known as LY-3437943 is an experimental medication developed by Eli Lilly for obesity, overweight conditions, and metabolic diseases like type 2 diabetes. It activates three hormone receptors at once: GLP-1 glucagon-like peptide-1 , GIP glucose-dependent insulinotropic polypeptide , and glucagon receptors. These pathways control appetite, insulin signaling, and energy use.
As noted by Louis Aronne in the New England Journal of Medicine, triple-agonist therapies like retatrutide lead to major body weight drops by affecting appetite, glucose handling, and energy spending together. Participants on higher doses saw some of the biggest weight losses in obesity drug trials. Jastreboff, Ania M., et al. "Triple, hormone-receptor agonist retatrutide for obesity, a phase 2 trial." New England Journal of Medicine 389.6 2023 : 514-526.
The drug uses once-weekly subcutaneous injections and is now in phase 3 trials for long-term safety and efficacy.
Phase 2 trials with adults who had obesity or were overweight examined various weekly subcutaneous doses to find the best mix of benefits and tolerance. The doses included:
Higher amounts generally brought bigger changes in weight and markers like blood glucose and insulin response. Participants receiving higher doses of retatrutide achieved mean weight reductions approaching 24% of baseline body weight after 48 weeks., Louis Aronne, New England Journal of Medicine.
You can model these schedules with Peptide Atlas' Dosage & Cycle Planner /tools/peptide-dosage-planner . Kaur, Manmeet, and Saurav Misra. "A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity." European Journal of Clinical Pharmacology 80.5 2024 : 669-676.
Retatrutide uses a titration method where doses rise slowly over time to boost tolerance and cut gastrointestinal issues. This matches the approach for other incretin therapies, as jumping to high doses often causes nausea, vomiting, or diarrhea that stops use.
Trials raised doses about every four weeks, starting low and moving to full levels. This lets the body adjust to shifts in digestion, hunger signals, and hormone activity. Check peptide terms in our Peptide Glossary /tools/peptide-glossary .
As Daniel Drucker notes in Cell Metabolism, GLP-1 receptor agonists slow stomach emptying and affect fullness signals, so escalation improves tolerance., Daniel Drucker, Cell Metabolism. With retatrutide's added GIP and glucagon action, slow increases aid smooth adaptation.
Dose level directly shaped outcomes in trials. The 1 mg starting point offered basic tolerance data with minor weight drops. At 4 mg and 8 mg, losses grew, with 8 mg hitting strong results.
The 12 mg dose delivered the peak effects, nearing 24% mean weight reduction at 48 weeks. These stand among the largest in obesity drug studies. Higher doses also improved blood sugar and insulin sensitivity.
Gastrointestinal side effects rise with dose due to hormone effects on gut and appetite. Titration cuts these risks by allowing adjustment. Trials showed most issues at higher levels but managed through slow ramps.
For research, tools like the Reconstitution Calculator /tools/peptide-reconstitution-calculator help prepare injections accurately. Phase 3 trials now test long-term safety.
Unlike single GLP-1 agonists or dual types, retatrutide hits three receptors for broader metabolic action. This leads to greater weight loss potential. Dosing needs careful steps due to its strength.
Retatrutide remains investigational, with phase 3 trials ongoing for obesity and related conditions. Trial data guide future use if approved. Researchers track weight loss, metabolic gains, and side effects across doses.
In summary, retatrutide's dosing from 1 to 12 mg weekly with titration maximizes benefits like 24% weight loss while handling sides. Use Free peptide tools /tools for research planning. Phase 3 results will shape guidelines.
---
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Retatrutide 20mg /product/retatrutide-20mg | ≥98% | 20mg | $99.00 |
| Retatrutide 10mg /product/retatrutide-10mg | ≥98% | 10mg | $64.00 |
Browse Full Catalog → /catalog
Peptides referenced: Retatrutide, Glucagon, GLP-1.
Related reading: Finasteride for Male Pattern Hair Loss: Uses and Facts, Semaglutide (Ozempic®): Uses, Dosing, and Key Facts for Type 2 Diabetes, Core Terms and Conditions for Research Compound Sales, Longevity Blood Testing in Canada: 43 Key Biomarkers.